Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates

Chemistry and Biology

Volumn 21, Issue 9, 2014, Pages 1115-1142

  Doak, Bradley Croy ^a   Over, Björn ^b   Giordanetto, Fabrizio ^c   Kihlberg, Jan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Taros Chemicals GmbH and Co KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; CARDIAC GLYCOSIDE; CYCLOSPORIN DERIVATIVE; ERYTHRONOLIDE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; KITASAMYCIN DERIVATIVE; NATURAL PRODUCT; NONSTRUCTURAL PROTEIN 3 INHIBITOR; NONSTRUCTURAL PROTEIN 4A INHIBITOR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEPTIDE DERIVATIVE; PRODRUG; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN; RIFAMYCIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; DRUG; MACROCYCLIC COMPOUND;

CYCLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG DOSE; DRUG FORMULATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSPORT; EFFUSION; HUMAN; HYDROGEN BOND; MOLECULAR WEIGHT; NONHUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; REVIEW; CHEMISTRY; DRUG DELIVERY SYSTEM; FACTUAL DATABASE; METABOLISM;

ADMINISTRATION, ORAL; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MACROCYCLIC COMPOUNDS; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; PROTEASE INHIBITORS;

EID: 84909586310     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.08.013     Document Type: Review

References (291)

1. Abad-Zapatero, C. (2007). A sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond. Drug Discov. Today 12, 995-997.
2. Agrawal, S., Ashokraj, Y., Bharatam, P.V., Pillai, O., and Panchagnula, R. (2004). Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur. J. Pharm. Sci. 22, 127-144.
3. Ahmad, S., Hunter, L., Qin, A., Mann, B.J., and van Hoek, M.L. (2010). Azithromycin effectiveness against intracellular infections of Francisella. BMC Microbiol. 10, 123.
4. Alex, A., Millan, D.S., Perez, M., Wakenhut, F., and Whitlock, G.A. (2011). Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. MedChemComm 2, 669-674.
5. Ali, A., Aydin, C., Gildemeister, R., Romano, K.P., Cao, H., Ozen, A., Soumana, D., Newton, A., Petropoulos, C.J., Huang, W., and Schiffer, C.A. (2013). Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem. Biol. 8, 1469-1478.
6. Alsenz, J., Steffen, H., and Alex, R. (1998). Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 15, 423-428.
7. Annaert, P., Ye, Z.W., Stieger, B., and Augustijns, P. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40, 163-176.
8. Arasappan, A., Bennett, F., Bogen, S.L., Venkatraman, S., Blackman, M., Chen, K.X., Hendrata, S., Huang, Y., Huelgas, R.M., Nair, L., et al. (2010). Discovery of Narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med Chem Lett 1, 64-69.
9. Artursson, P., Palm, K., and Luthman, K. (2012). Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 64, 280-289.
10. Ashwood, V.A., Field, M.J., Horwell, D.C., Julien-Larose, C., Lewthwaite, R.A., McCleary, S., Pritchard, M.C., Raphy, J., and Singh, L. (2001). Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. J. Med. Chem. 44, 2276-2285.
11. Aspeslet, L., Freitag, D., Trepanier, D., Abel, M., Naicker, S., Kneteman, N., Foster, R., and Yatscoff, R. (2001). ISA(TX)247: a novel calcineurin inhibitor. Transplant. Proc. 33, 1048-1051.
12. Augustijns, P.F., Bradshaw, T.P., Gan, L.S.L., Hendren, R.W., and Thakker, D.R. (1993). Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197, 360-365.
13. Avdeef, A. (2012). Absorption and Drug Development: Solubility, Permeability, and Charge State, Second Edition. (Hoboken, NJ: John Wiley & Sons).
14. Bacchi, A., Pelizzi, G., Nebuloni, M., and Ferrari, P. (1998). Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O. J. Med. Chem. 41, 2319-2332.
15. Baciewicz, A.M., Chrisman, C.R., Finch, C.K., and Self, T.H. (2013). Update on rifampin, rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 29, 1-12.
16. Balimane, P.V., Han, Y.H., and Chong, S. (2006). Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8, E1-E13.
17. Beck, J.G., Chatterjee, J., Laufer, B., Kiran, M.U., Frank, A.O., Neubauer, S., Ovadia, O., Greenberg, S., Gilon, C., Hoffman, A., and Kessler, H. (2012). Intestinal permeability of cyclic peptides: common key backbone motifs identified. J. Am. Chem. Soc. 134, 12125-12133.
18. Belz, G.G., Matthews, J., Sauer, U., Stern, H., and Schneider, B. (1984). Pharmacodynamic effects of ouabain following single sublingual and intravenous doses in normal subjects. Eur. J. Clin. Pharmacol. 26, 287-292.
19. Bennani, Y.L. (2011). Drug discovery in the next decade: innovation needed ASAP. Drug Discov. Today 16, 779-792.
20. Bergström, C.A.S., Bolin, S., Artursson, P., Rönn, R., and Sandström, A. (2009). Hepatitis C virus NS3 protease inhibitors: large, flexible molecules of peptide origin show satisfactory permeability across Caco-2 cells. Eur. J. Pharm. Sci. 38, 556-563.
21. Bickerton, G.R., Paolini, G.V., Besnard, J., Muresan, S., and Hopkins, A.L. (2012). Quantifying the chemical beauty of drugs. Nat. Chem. 4, 90-98.
22. Bilello, J.P., Dousson, C.B., Colla, M.L., Chapron, C., Bhadresa, S., Camire, M., Serra, I., Gillum, J.M., Lallos, L.B., McCarville, J.F., et al. (2011). Antiviral and Preclinical Profiles of HCV NS5A Inhibitors IDX380 and IDX719. Proceedings of the 18th International Symposium on Hepatitis C Virus and Related Viruses, Seattle; September 8-12, 2011.
23. Bissantz, C., Kuhn, B., and Stahl, M. (2010). A medicinal chemist's guide to molecular interactions. J. Med. Chem. 53, 5061-5084.
24. Bjornsson, T.D., and Mahony, C. (1983). Clinical pharmacokinetics of dipyridamole. Thromb. Res. 4, 93-104.
25. Blaschke, T.F., and Skinner, M.H. (1996). The clinical pharmacokinetics of rifabutin. Clin. Infect. Dis. 22 (Suppl 1), S15-S21, discussion S21-S12.
26. Blocka, K. (1983). Auranofin versus injectable gold. Comparison of pharmacokinetic properties. Am. J. Med. 75, 114-122.
27. Bockus, A.T., McEwen, C.M., and Lokey, R.S. (2013). Form and function in cyclic peptide natural products: a pharmacokinetic perspective. Curr. Top. Med. Chem. 13, 821-836.
28. Bogdan, A.R., Davies, N.L., and James, K. (2011). Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range. Org. Biomol. Chem. 9, 7727-7733.
29. Bosnar, M., Kelnerić, Z., Munić, V., Eraković, V., and Parnham, M.J. (2005). Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob. Agents Chemother. 49, 2372-2377.
30. Bousquet, L., Roucairol, C., Hembury, A., Nevers, M.C., Creminon, C., Farinotti, R., and Mabondzo, A. (2008). Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res. Hum. Retroviruses 24, 1147-1154.
31. Brandt, W., Haupt, V.J., and Wessjohann, L.A. (2010). Chemoinformatic analysis of biologically active macrocycles. Curr. Top. Med. Chem. 10, 1361-1379.
32. Brook, I. (1998). Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance. Clin. Pharmacokinet. 34, 303-310.
33. Brufani, M., Fedeli, W., Giacomello, G., and Vaciago, A. (1964). The x-ray analysis of the structure of rifamycin B. Experientia 20, 339-342.
34. Brufani, M., Fedeli, W., Giacomello, G., and Vaciago, A. (1967). The x-ray analysis of the structure of rifamycin Y. Experientia 23, 508-512.
35. Bunnage, M.E. (2011). Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335-339.
36. Burman, W.J., Gallicano, K., and Peloquin, C. (2001). Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40, 327-341.
37. Casey, M.L., and Whitlock, H.W. (1975). Determination of the solution conformation of rifamycin S and derivatives by nuclear magnetic resonance. J. Am. Chem. Soc. 97, 6231-6236.
38. Cavet, M.E., West, M., and Simmons, N.L. (1996). Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118, 1389-1396.
39. Cermanova, J., Fuksa, L., Brcakova, E., Hroch, M., Kucera, O., Kolouchova, G., Hirsova, P., Malakova, J., Staud, F., Martinkova, J., et al. (2010). Up-regulation of renal Mdr1 and Mrp2 transporters during amiodarone pretreatment in rats. Pharmacol. Res. 61, 129-135.
40. Chauvin, B., Drouot, S., Barrail-Tran, A., and Taburet, A.M. (2013). Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin. Pharmacokinet. 52, 815-831.
41. ChemAxon (2014). Instant JChem 6.2.1, 2014, ChemAxon. http://www.chemaxon.com.
42. Chen, C., Hanson, E., Watson, J.W., and Lee, J.S. (2003). P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab. Dispos. 31, 312-318.
43. Chu, X., Philip, G., and Evers, R. (2012). Comments on Mougey et al. (2009): absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19: 129-138. Pharmacogenet. Genomics 22, 319-322.
44. Ciesla, S.L., Trahan, J., Wan, W.B., Beadle, J.R., Aldern, K.A., Painter, G.R., and Hostetler, K.Y. (2003). Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59, 163-171.
45. Coburn, C.A., Meinke, P.T., Chang, W., Fandozzi, C.M., Graham, D.J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., et al. (2013). Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8, 1930-1940.
46. Cohen, A.F., Kroon, R., Schoemaker, H.C., Breimer, D.D., Van Vliet-Verbeek, A., and Brandenburg, H.C. (1993). The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay. Br. J. Clin. Pharmacol. 35, 136-142.
47. Courtney, R., Pai, S., Laughlin, M., Lim, J., and Batra, V. (2003). Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47, 2788-2795.
48. Cragg, G.M. (1998). Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development. Med. Res. Rev. 18, 315-331.
49. Dancey, J. (2010). mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7, 209-219.
50. Deeks, E.D. (2014). Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs 74, 195-206.
51. DeGoey, D.A., Randolph, J.T., Liu, D., Pratt, J., Hutchins, C., Donner, P., Krueger, A.C., Matulenko, M., Patel, S., Motter, C.E., et al. (2014). Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J. Med. Chem. 57, 2047-2057.
52. DeGorter, M.K., Xia, C.Q., Yang, J.J., and Kim, R.B. (2012). Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 52, 249-273.
53. Delorbe, J.E., Clements, J.H., Whiddon, B.B., and Martin, S.F. (2010). Thermodynamic and structural effects of macrocyclization as a constraining method in protein-ligand interactions. ACS Med Chem Lett 1, 448-452.
54. Demel, M.A., Schwaha, R., Krämer, O., Ettmayer, P., Haaksma, E.E., and Ecker, G.F. (2008). In silico prediction of substrate properties for ABC-multi-drug transporters. Expert Opin. Drug Metab. Toxicol. 4, 1167-1180.
55. Desai, P.V., Raub, T.J., and Blanco, M.J. (2012). How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorg. Med. Chem. Lett. 22, 6540-6548.
56. Desai, P.V., Sawada, G.A., Watson, I.A., and Raub, T.J. (2013). Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. Mol. Pharm. 10, 1249-1261.
57. DiNunzio, J.C., Zhang, F., Martin, C., and McGinity, J.W. (2012). Melt extrusion. In Formulating Poorly Water Soluble Drugs, R.O. Williams, III, A.B. Watts, and D.A. Miller, eds. (New York: Springer), pp. 311-362.
58. Driggers, E.M., Hale, S.P., Lee, J., and Terrett, N.K. (2008). The exploration of macrocycles for drug discovery - an underexploited structural class. Nat. Rev. Drug Discov. 7, 608-624.
59. Duan, J., Yong, C.-L., Garneau, M., Amad, M., Bolger, G., De Marte, J., Montpetit, H., Otis, F., Jutras, M., Rhéaume, M., et al. (2012). Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor. Xenobiotica 42, 164-172.
60. Edwards, G., Dingsdale, A., Helsby, N., Orme, M.L., and Breckenridge, A.M. (1988). The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur. J. Clin. Pharmacol. 35, 681-684.
61. Egan, W.J., Merz, K.M., Jr., and Baldwin, J.J. (2000). Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43, 3867-3877.
62. Eisler, R. (2003). Chrysotherapy: a synoptic review. Inflamm. Res. 52, 487-501.
63. El Tayar, N., Mark, A.E., Vallat, P., Brunne, R.M., Testa, B., and van Gunsteren, W.F. (1993). Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J. Med. Chem. 36, 3757-3764.
64. Ellard, G.A., and Fourie, P.B. (1999). Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int. J. Tuberc. Lung Dis 3, S301-S308, discussion S317-S321.
65. Elsby, R., Surry, D.D., Smith, V.N., and Gray, A.J. (2008). Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38, 1140-1164.
66. Ertl, P., Rohde, B., and Selzer, P. (2000). Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43, 3714-3717.
67. Ettorre, A., D'Andrea, P., Mauro, S., Porcelloni, M., Rossi, C., Altamura, M., Catalioto, R.M., Giuliani, S., Maggi, C.A., and Fattori, D. (2011). hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg. Med. Chem. Lett. 21, 1807-1809.
68. Fahr, A. (1993). Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24, 472-495.
69. Fatouros, D.G., Karpf, D.M., Nielsen, F.S., and Mullertz, A. (2007). Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther. Clin. Risk. Manag. 3, 591-604.
70. Ferlini, C., Gallo, D., and Scambia, G. (2008). New taxanes in development. Expert Opin. Investig. Drugs 17, 335-347.
71. Fitzgerald, D.P., Emerson, D.L., Qian, Y., Anwar, T., Liewehr, D.J., Steinberg, S.M., Silberman, S., Palmieri, D., and Steeg, P.S. (2012). TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol. Cancer Ther. 11, 1959-1967.
72. Flisiak, R., Jaroszewicz, J., Flisiak, I., and Łapiński, T. (2012). Update on alisporivir in treatment of viral hepatitis C. Expert Opin. Investig. Drugs 21, 375-382.
73. Fox, L.M. (2006). Ivermectin: uses and impact 20 years on. Curr. Opin. Infect. Dis. 19, 588-593.
74. Franke, R.M., Baker, S.D., Mathijssen, R.H., Schuetz, E.G., and Sparreboom, A. (2008). Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin. Pharmacol. Ther. 84, 704-709.
75. Fukuda, Y., Takenaka, K., Sparreboom, A., Cheepala, S.B., Wu, C.P., Ekins, S., Ambudkar, S.V., and Schuetz, J.D. (2013). Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol. Pharmacol. 84, 361-371.
76. Gabardi, S., and Baroletti, S.A. (2010). Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 30, 1044-1056.
77. Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O'Boyle, D.R., 2nd., et al. (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100.
78. Gao, L., Li, J., Kasserra, C., Song, Q., Arjomand, A., Hesk, D., and Chowdhury, S.K. (2011). Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies. Anal. Chem. 83, 5607-5616.
79. Garver, E., Hugger, E.D., Shearn, S.P., Rao, A., Dawson, P.A., Davis, C.B., and Han, C. (2008). Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat. Drug Metab. Dispos. 36, 2492-2498.
80. Geers, S., Lowinger, M., Mckelvey, C.A., Meyer, R.F., and Zhang, D. October 2011. Polymer formulations of CETP inhibitors. U.S. patent 8030359B2.
81. Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A. (2001). Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598.
82. Gertz, M., Harrison, A., Houston, J.B., and Galetin, A. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38, 1147-1158.
83. Ghose, A.K., Herbertz, T., Hudkins, R.L., Dorsey, B.D., and Mallamo, J.P. (2012). Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem. Neurosci. 3, 50-68.
84. Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L.R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., et al.; International Transporter Consortium (2010). Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236.
85. Giordanetto, F., and Kihlberg, J. (2014). Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57, 278-295.
86. Gleeson, M.P. (2008). Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51, 817-834.
87. Goetz, G.H., Farrell, W., Shalaeva, M., Sciabola, S., Anderson, D., Yan, J., Philippe, L., and Shapiro, M.J. (2014). High throughput method for the indirect detection of intramolecular hydrogen bonding. J. Med. Chem. 57, 2920-2929.
88. Gonc¸alves, J.E., Ballerini Fernandes, M., Chiann, C., Gai, M.N., De Souza, J., and Storpirtis, S. (2012). Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells. Biopharm. Drug Dispos. 33, 316-323.
89. GOSTAR (2013). About GOSTAR. https://gostardb.com/gostar/doc/HyperlinkDownloadPDF.pdf.
90. Griffin, J., Fletcher, N., Clemence, R., Blanchflower, S., and Brayden, D.J. (2005). Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J. Vet. Pharmacol. Ther. 28, 257-265.
91. Guimarães, C.R.W., Mathiowetz, A.M., Shalaeva, M., Goetz, G., and Liras, S. (2012). Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Model. 52, 882-890.
92. Guo, A., Marinaro, W., Hu, P., and Sinko, P.J. (2002). Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. 30, 457-463.
93. Hande, K.R. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34, 1514-1521.
94. Hann, M.M., and Keserü, G.M. (2012). Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 11, 355-365.
95. Havard, C.W., and Fonseca, V. (1990). New treatment approaches to myasthenia gravis. Drugs 39, 66-73.
96. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., and Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51.
97. Hitchcock, S.A. (2012). Structural modifications that alter the P-glycoprotein efflux properties of compounds. J. Med. Chem. 55, 4877-4895.
98. Hopkins, A.L., Mason, J.S., and Overington, J.P. (2006). Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127-136.
99. Hopkins, S., Scorneaux, B., Huang, Z., Murray, M.G., Wring, S., Smitley, C., Harris, R., Erdmann, F., Fischer, G., and Ribeill, Y. (2010). SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 54, 660-672.
100. Hosoe, K., Mae, T., Konishi, E., Fujii, K., Yamashita, K., Yamane, T., Hidaka, T., and Ohashi, T. (1996). Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob. Agents Chemother. 40, 2749-2755.
101. Hostetler, K.Y. (2010). Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2, 2213-2225.
102. Hsu, A., Granneman, G.R., and Bertz, R.J. (1998). Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 35, 275-291.
103. Iacono, A.T., and Bartley, G. January 2002. Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease. U.S. patent 20020006901.
104. Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., and Grove, J.R. (1999). MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88, 28-33.
105. Ito, S., Nasu, R., Tsujimoto, M., Murakami, H., Ohtani, H., and Sawada, Y. (2007). Effect of macrolide antibiotics on uptake of digoxin into rat liver. Biopharm. Drug Dispos. 28, 113-123.
106. Jansma, A., Zhang, Q., Li, B., Ding, Q., Uno, T., Bursulaya, B., Liu, Y., Furet, P., Gray, N.S., and Geierstanger, B.H. (2007). Verification of a designed intramolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance spectroscopy. J. Med. Chem. 50, 5875-5877.
107. Jiang, H., Zeng, J., Li, W., Bifano, M., Gu, H., Titsch, C., Easter, J., Burrell, R., Kandoussi, H., Aubry, A.F., and Arnold, M.E. (2012). Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay. Anal. Chem. 84, 10031-10037.
108. Jiang, Y., Andrews, S.W., Condroski, K.R., Buckman, B., Serebryany, V., Wenglowsky, S., Kennedy, A.L., Madduru, M.R., Wang, B., Lyon, M., et al. (2014). Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem. 57, 1753-1769.
109. Jing, Y.R., Zhou, W., Li, W.L., Zhao, L.X., and Wang, Y.F. (2014). The synthesis of novel taxoids for oral administration. Bioorg. Med. Chem. 22, 194-203.
110. Johnson, T.W., Dress, K.R., and Edwards, M. (2009). Using the Golden Triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 19, 5560-5564.
111. Josephson, K., Ricardo, A., and Szostak, J.W. (2014). mRNA display: from basic principles to macrocycle drug discovery. Drug Discov. Today 19, 388-399.
112. Kalliokoski, A., and Niemi, M. (2009). Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705.
113. Kansy, M., Senner, F., and Gubernator, K. (1998). Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007-1010.
114. Kazmierski, W.M., Maynard, A., Duan, M., Baskaran, S., Botyanszki, J., Crosby, R., Dickerson, S., Tallant, M., Grimes, R., Hamatake, R., et al. (2014). Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound. J. Med. Chem. 57, 2058-2073.
115. Keogh, J.P., and Kunta, J.R. (2006). Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27, 543-554.
116. Kerns, E.H., and Di, L. (2008). Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. (Amsterdam, Boston: Academic Press).
117. Kesavan, S., and Marcaurelle, L.A. (2013). Translational synthetic chemistry. Nat. Chem. Biol. 9, 210-213.
118. Khojasteh, S.C., Wong, H., and Hop, C.E. (2011). Transporters. In Drug Metabolism and Pharmacokinetics Quick Guide, S.C. Khojasteh, H. Wong, and C.E.C.A. Hop, eds. (New York: Springer), pp. 57-72.
119. Kim, K.A., Lee, H.M., Joo, H.J., Park, I.B., and Park, J.Y. (2013). Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J. Clin. Pharmacol. 53, 1186-1193.
120. Kinch, M.S., Haynesworth, A., Kinch, S.L., and Hoyer, D. (2014). An overview of FDA-approved new molecular entities: 1827-2013. Drug Discov. Today. 19, 1033-1039.
121. Kirchner, G.I., Meier-Wiedenbach, I., and Manns, M.P. (2004). Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43, 83-95.
122. Kirken, R.A., and Wang, Y.L. (2003). Molecular actions of sirolimus: sirolimus and mTor. Transplant. Proc. 35 (3 Suppl), 227S-230S.
123. Kis, O., Zastre, J.A., Hoque, M.T., Walmsley, S.L., and Bendayan, R. (2013). Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm. Res. 30, 1050-1064.
124. Kiser, J.J., Lichtenstein, K.A., Anderson, P.L., and Fletcher, C.V. (2006). Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 26, 511-514.
125. Kola, I., and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715.
126. Kostewicz, E.S., Brauns, U., Becker, R., and Dressman, J.B. (2002). Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 19, 345-349.
127. Kuhn, B., Mohr, P., and Stahl, M. (2010). Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53, 2601-2611.
128. Kumar, S., Tan, E.Y., Hartmann, G., Biddle, Z., Bergman, A.J., Dru, J., Ho, J.Z., Jones, A.N., Staskiewicz, S.J., Braun, M.P., et al. (2010). Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab. Dispos. 38, 474-483.
129. Lajiness, M.S., Vieth, M., and Erickson, J. (2004). Molecular properties that influence oral drug-like behavior. Curr. Opin. Drug Discov. Devel. 7, 470-477.
130. Lam, J.L., Okochi, H., Huang, Y., and Benet, L.Z. (2006). In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34, 1336-1344.
131. Lamarre, D., Anderson, P.C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D.R., Cartier, M., Cordingley, M.G., et al. (2003). An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189.
132. Lamoureux, F., Picard, N., Boussera, B., Sauvage, F.-L., and Marquet, P. (2012). Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. Fundam. Clin. Pharmacol. 26, 463-472.
133. Lan, T., Rao, A., Haywood, J., Davis, C.B., Han, C., Garver, E., and Dawson, P.A. (2009). Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab. Dispos. 37, 2375-2382.
134. Lanier, E.R., Ptak, R.G., Lampert, B.M., Keilholz, L., Hartman, T., Buckheit, R.W., Jr., Mankowski, M.K., Osterling, M.C., Almond, M.R., and Painter, G.R. (2010). Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob. Agents Chemother. 54, 2901-2909.
135. Laurence, C., Brameld, K.A., Graton, J., Le Questel, J.-Y., and Renault, E. (2009). The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists. J. Med. Chem. 52, 4073-4086.
136. Le Tiec, C., Barrail, A., Goujard, C., and Taburet, A.M. (2005). Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050.
137. Leeson, P.D., and Springthorpe, B. (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881-890.
138. Lepist, E.I., Phan, T.K., Roy, A., Tong, L., Maclennan, K., Murray, B., and Ray, A.S. (2012). Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob. Agents Chemother. 56, 5409-5413.
139. Li, J.W.H., and Vederas, J.C. (2009). Drug discovery and natural products: end of an era or an endless frontier? Science 325, 161-165.
140. Li, C., Liu, T., Cui, X., Uss, A.S., and Cheng, K.C. (2007). Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J. Biomol. Screen. 12, 1084-1091.
141. Li, Y., Theuretzbacher, U., Clancy, C.J., Nguyen, M.H., and Derendorf, H. (2010). Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin. Pharmacokinet. 49, 379-396.
142. Lin, J.H., and Yamazaki, M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98.
143. Link, J.O., Taylor, J.G., Xu, L., Mitchell, M., Guo, H., Liu, H., Kato, D., Kirschberg, T., Sun, J., Squires, N., et al. (2014). Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57, 2033-2046.
144. Lipinski, C.A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249.
145. Lipinski, C.A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today. Technol. 1, 337-341.
146. Lipinski, C. (2012). Chris Lipinski. Interview by Peter Kirkpatrick. Nat. Rev. Drug Discov. 11, 900-901.
147. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3-25.
148. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26.
149. Lipp, H.P. (2010). Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br. J. Clin. Pharmacol. 70, 471-480.
150. Liu, G., Franssen, E., Fitch, M.I., and Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15, 110-115.
151. Liverton, N.J., Carroll, S.S., Dimuzio, J., Fandozzi, C., Graham, D.J., Hazuda, D., Holloway, M.K., Ludmerer, S.W., McCauley, J.A., McIntyre, C.J., et al. (2010). MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 54, 305-311.
152. Loos, U., Musch, E., Jensen, J.C., Mikus, G., Schwabe, H.K., and Eichelbaum, M. (1985). Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63, 1205-1211.
153. Lovering, F. (2013). Escape from Flatland 2: complexity and promiscuity. MedChemComm 4, 515-519.
154. Lovering, F., Bikker, J., and Humblet, C. (2009). Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756.
155. Lown, K.S., Mayo, R.R., Leichtman, A.B., Hsiao, H.L., Turgeon, D.K., Schmiedlin-Ren, P., Brown, M.B., Guo, W., Rossi, S.J., Benet, L.Z., and Watkins, P.B. (1997). Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260.
156. Luber, A.D., Brower, R., Kim, D., Silverman, R., Peloquin, C.A., and Frank, I. (2007). Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 8, 457-464.
157. Maertens, J.A. (2004). History of the development of azole derivatives. Clin. Microbiol. Infect. 10 (Suppl 1), 1-10.
158. Mallinson, J., and Collins, I. (2012). Macrocycles in new drug discovery. Future Med. Chem. 4, 1409-1438.
159. Mannhold, R., Poda, G.I., Ostermann, C., and Tetko, I.V. (2009). Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds. J. Pharm. Sci. 98, 861-893.
160. Manns, M.P., and von Hahn, T. (2013). Novel therapies for hepatitis C - one pill fits all? Nat. Rev. Drug Discov. 12, 595-610.
161. Marsault, E., and Peterson, M.L. (2011). Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 54, 1961-2004.
162. Marty, F.M., Winston, D.J., Rowley, S.D., Vance, E., Papanicolaou, G.A., Mullane, K.M., Brundage, T.M., Robertson, A.T., Godkin, S., Momméja-Marin, H., and Boeckh, M.; CMX001-201 Clinical Study Group (2013). CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369, 1227-1236.
163. McChesney, J.D., Tapolsky, G., Emerson, D.E., Marshall, J., Ahmed, T., Cohn, A., Kurman, M., and Modiano, M. October 2008. Biologically active taxane analogs and methods of treatment by oral administration. U.S. patent WO2008121476A1.
164. McDonagh, A.F., and Lightner, D.A. (2007). Influence of conformation and intramolecular hydrogen bonding on the acyl glucuronidation and biliary excretion of acetylenic bis-dipyrrinones related to bilirubin. J. Med. Chem. 50, 480-488.
165. McPhee, F., Sheaffer, A.K., Friborg, J., Hernandez, D., Falk, P., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., et al. (2012). Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob. Agents Chemother. 56, 5387-5396.
166. Meanwell, N.A. (2011). Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24, 1420-1456.
167. Medina-Franco, J.L., Martinez-Mayorga, K., and Meurice, N. (2014). Balancing novelty with confined chemical space in modern drug discovery. Expert Opin. Drug. Discov. 9, 151-165.
168. Meerum Terwogt, J.M., Malingré, M.M., Beijnen, J.H., ten Bokkel Huinink, W.W., Rosing, H., Koopman, F.J., van Tellingen, O., Swart, M., and Schellens, J.H. (1999). Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5, 3379-3384.
169. Meng, X., Mojaverian, P., Doedée, M., Lin, E., Weinryb, I., Chiang, S.T., and Kowey, P.R. (2001). Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am. J. Cardiol. 87, 432-435.
170. Mor, N., Simon, B., Mezo, N., and Heifets, L. (1995). Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39, 2073-2077.
171. Morphy, R. (2006). The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 49, 2969-2978.
172. Mougey, E.B., Feng, H., Castro, M., Irvin, C.G., and Lima, J.J. (2009). Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 19, 129-138.
173. Mougey, E.B., Lang, J.E., Wen, X., and Lima, J.J. (2011). Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J. Clin. Pharmacol. 51, 751-760.
174. Mullard, A. (2013). 2012 FDA drug approvals. Nat. Rev. Drug Discov. 12, 87-90.
175. Munić, V., Kelnerić, Z., Mikac, L., and Eraković Haber, V. (2010). Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur. J. Pharm. Sci. 41, 86-95.
176. Muresan, S., Petrov, P., Southan, C., Kjellberg, M.J., Kogej, T., Tyrchan, C., Varkonyi, P., and Xie, P.H. (2011). Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data. Drug Discov. Today 16, 1019-1030.
177. Neszmélyi, A., Machytka, D., Kmety, A., Sándor, P., and Lukacs, G. (1989). Solution conformation of the disaccharide of avermectin B1a examined by NMR spectroscopy and nuclear Overhauser enhancement restrained hard-sphere exo-anomeric effect calculation. J. Antibiot. (Tokyo) 42, 1494-1501.
178. Newman, D.J. (2008). Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 51, 2589-2599.
179. Nicholls, M.G., Lewis, L.K., Yandle, T.G., Lord, G., McKinnon, W., and Hilton, P.J. (2009). Ouabain, a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease. Fact or fantasy? J. Hypertens. 27, 3-8.
180. Nomeir, A.A., Kumari, P., Hilbert, M.J., Gupta, S., Loebenberg, D., Cacciapuoti, A., Hare, R., Miller, G.H., Lin, C.C., and Cayen, M.N. (2000). Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. 44, 727-731.
181. Nordqvist, A., Nilsson, J., Lindmark, T., Eriksson, A., Garberg, P., and Kihlen, M. (2004). A general model for prediction of Caco-2 cell permeability. QSAR Comb. Sci. 23, 303-310.
182. Nozinic, D., Milic, A., Mikac, L., Ralic, J., Padovan, J., and Antolovic, R. (2010). Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1 assays. Croat. Chem. Acta 83, 323-331.
183. O'Connor, C.J., Beckmann, H.S., and Spring, D.R. (2012). Diversity-oriented synthesis: producing chemical tools for dissecting biology. Chem. Soc. Rev. 41, 4444-4456.
184. O'Driscoll, C.M., and Griffin, B.T. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev. 60, 617-624.
185. O'Neill, V.J., and Twelves, C.J. (2002). Oral cancer treatment: developments in chemotherapy and beyond. Br. J. Cancer 87, 933-937.
186. Obrecht, D., Chevalier, E., Moehle, K., and Robinson, J.A. (2012). β-Hairpin protein epitope mimetic technology in drug discovery. Drug Discov. Today. Technol. 9, e1-e70.
187. Ochs, H.R., Bodem, G., and Greenblatt, D.J. (1981). Effect of dose on bioavailability of oral digoxin. Eur. J. Clin. Pharmacol. 19, 53-55.
188. Okumu, A., DiMaso, M., and Löbenberg, R. (2008). Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res. 25, 2778-2785.
189. Omura, S., Iwasaki, S., Omura, S., and Sunazuka, T. (2002). Chemical modification of macrolides. In Macrolide Antibiotics: Chemistry, Biology, and Practice, S. Omura, ed. (San Diego: Academic Press), p. 99.
190. OpenEye (2014). OEChem, version 2.5.1.4, OpenEye Scientific Software, Inc.. (Santa Fe, NM: OpenEye Scientific Software).
191. Over, B., McCarren, P., Artursson, P., Foley, M., Giordanetto, F., Grönberg, G., Hilgendorf, C., Lee, M.D., 4th, Matsson, P., Muncipinto, G., et al. (2014). Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties. J. Med. Chem. 57, 2746-2754.
192. Pachot, J.I., Botham, R.P., Haegele, K.D., and Hwang, K. (2003). Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci. 6, 1-12.
193. Padovan, J., Ralić, J., Letfus, V., Milić, A., and Bencetić Mihaljević, V. (2012). Investigating the barriers to bioavailability of macrolide antibiotics in the rat. Eur. J. Drug Metab. Pharmacokinet. 37, 163-171.
194. Painter, G.R., and Hostetler, K.Y. (2004). Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 22, 423-427.
195. Palm, K., Stenberg, P., Luthman, K., and Artursson, P. (1997). Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568-571.
196. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S., and Hopkins, A.L. (2006). Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815.
197. Parker, A.J., and Houston, J.B. (2008). Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab. Dispos. 36, 1375-1384.
198. Patel, J., Buddha, B., Dey, S., Pal, D., and Mitra, A.K. (2004). In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther. 11, 262-277.
199. Patel, P., Patel, H., Panchal, S., and Mehta, T. (2012). Formulation strategies for drug delivery of tacrolimus: an overview. Int J Pharm Investig 2, 169-175.
200. Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., and Schacht, A.L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214.
201. Pawarode, A., Shukla, S., Minderman, H., Fricke, S.M., Pinder, E.M., O'Loughlin, K.L., Ambudkar, S.V., and Baer, M.R. (2007). Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother. Pharmacol. 60, 179-188.
202. Peeters, J., Neeskens, P., Tollenaere, J.P., Van Remoortere, P., and Brewster, M.E. (2002). Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91, 1414-1422.
203. Perloff, E.S., Duan, S.X., Skolnik, P.R., Greenblatt, D.J., and von Moltke, L.L. (2005). Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33, 764-770.
204. Pharmaprojects (2013). http://www.citeline.com/products/pharmaprojects/.
205. Picard, N., Levoir, L., Lamoureux, F., Yee, S.W., Giacomini, K.M., and Marquet, P. (2011). Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 41, 752-757.
206. Pirsch, J.D., Miller, J., Deierhoi, M.H., Vincenti, F., and Filo, R.S. (1997). A comparison of tacrolimus (Fk506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63, 977-983.
207. Polishchuk, P.G., Madzhidov, T.I., and Varnek, A. (2013). Estimation of the size of drug-like chemical space based on GDB-17 data. J. Comput. Aided Mol. Des. 27, 675-679.
208. Prentice, A.G., and Glasmacher, A. (2005). Making sense of itraconazole pharmacokinetics. J. Antimicrob. Chemother. 56 (Suppl 1), i17-i22.
209. Price, D.A., Blagg, J., Jones, L., Greene, N., and Wager, T. (2009). Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin. Drug Metab. Toxicol. 5, 921-931.
210. Profit, L., Eagling, V.A., and Back, D.J. (1999). Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13, 1623-1627.
211. Ptachcinski, R.J., Burckart, G.J., and Venkataramanan, R. (1985). Cyclosporine. Drug Intell. Clin. Pharm. 19, 90-100.
212. Pyta, K., Przybylski, P., Klich, K., and Stefańska, J. (2012). A new model of binding of rifampicin and its amino analogues as zwitterions to bacterial RNA polymerase. Org. Biomol. Chem. 10, 8283-8297.
213. Rafi, S.B., Hearn, B.R., Vedantham, P., Jacobson, M.P., and Renslo, A.R. (2012). Predicting and improving the membrane permeability of peptidic small molecules. J. Med. Chem. 55, 3163-3169.
214. Ramsden, D., Tweedie, D.J., Chan, T.S., Taub, M.E., and Li, Y. (2014). Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab. Dispos. 42, 394-406.
215. Ranaldi, G., Islam, K., and Sambuy, Y. (1992). Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Agents Chemother. 36, 1374-1381.
216. Rand, A.C., Leung, S.S., Eng, H., Rotter, C.J., Sharma, R., Kalgutkar, A.S., Zhang, Y., Varma, M.V., Farley, K.A., Khunte, B., et al. (2012). Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). Medchemcomm 3, 1282-1289.
217. Rezai, T., Bock, J.E., Zhou, M.V., Kalyanaraman, C., Lokey, R.S., and Jacobson, M.P. (2006a). Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128, 14073-14080.
218. Rezai, T., Yu, B., Millhauser, G.L., Jacobson, M.P., and Lokey, R.S. (2006b). Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 128, 2510-2511.
219. Rodvold, K.A., George, J.M., and Yoo, L. (2011). Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin. Pharmacokinet. 50, 637-664.
220. Rosenquist, A˚., Samuelsson, B., Johansson, P.-O., Cummings, M.D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., Nilsson, M., et al. (2014). Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 57, 1673-1693.
221. Rothstein, D.M., Farquhar, R.S., Sirokman, K., Sondergaard, K.L., Hazlett, C., Doye, A.A., Gwathmey, J.K., Mullin, S., van Duzer, J., and Murphy, C.K. (2006). Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection. Antimicrob. Agents Chemother. 50, 3658-3664.
222. Roy, U., Chakravarty, G., Honer Zu Bentrup, K., and Mondal, D. (2009). Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol. Pharm. Bull. 32, 2002-2009.
223. Ruddigkeit, L., van Deursen, R., Blum, L.C., and Reymond, J.L. (2012). Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J. Chem. Inf. Model. 52, 2864-2875.
224. Sadowski, J., Gasteiger, J., and Klebe, G. (1994). Comparison of automatic three-dimensional model builders using 639 x-ray structures. J. Chem. Inf. Comput. Sci. 34, 1000-1008.
225. Saha, P., and Kou, J.H. (2000). Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur. J. Pharm. Biopharm. 50, 403-411.
226. Sandouk, P., Bouvier d'Yvoire, M., Chretien, P., Tillement, J.P., and Scherrmann, J.M. (1994). Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers. Biopharm. Drug Dispos. 15, 87-92.
227. Sasaki, S., Cho, N., Nara, Y., Harada, M., Endo, S., Suzuki, N., Furuya, S., and Fujino, M. (2003). Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J. Med. Chem. 46, 113-124.
228. Sauer, W.H.B., and Schwarz, M.K. (2003). Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 43, 987-1003.
229. Scannell, J.W., Blanckley, A., Boldon, H., and Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200.
230. Schoner, W., and Scheiner-Bobis, G. (2007). Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293, C509-C536.
231. Schreiber, S.L. (2000). Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969.
232. Scola, P.M., Sun, L.-Q., Wang, A.X., Chen, J., Sin, N., Venables, B.L., Sit, S.-Y., Chen, Y., Cocuzza, A., Bilder, D.M., et al. (2014). The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57, 1730-1752.
233. Segawa, M., Ogura, J., Seki, S., Itagaki, S., Takahashi, N., Kobayashi, M., Hirano, T., Yamaguchi, H., and Iseki, K. (2013). Rapid stimulating effect of the antiarrhythmic agent amiodarone on absorption of organic anion compounds. Drug Metab. Pharmacokinet. 28, 178-186.
234. Sehgal, S.N. (2003). Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35 (3, Suppl), 7S-14S.
235. Seithel, A., Eberl, S., Singer, K., Auge, D., Heinkele, G., Wolf, N.B., Dörje, F., Fromm, M.F., and König, J. (2007). The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35, 779-786.
236. Selva, E., and Lancini, G. (2010). Rifamycins, antibacterial antibiotics and their new applications. In Analogue-Based Drug Discovery II, J. Fischer and C.R. Ganellin, eds. (Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA), pp. 173-187.
237. Sensi, P. (1983). History of the development of rifampin. Rev. Infect. Dis. 5 (Suppl 3), S402-S406.
238. Shalaeva, M., Caron, G., Abramov, Y.A., O'Connell, T.N., Plummer, M.S., Yalamanchi, G., Farley, K.A., Goetz, G.H., Philippe, L., and Shapiro, M.J. (2013). Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using DlogP as a tool. J. Med. Chem. 56, 4870-4879.
239. Sheng, X.C., Appleby, T., Butler, T., Cai, R., Chen, X., Cho, A., Clarke, M.O., Cottell, J., Delaney, W.E., 4th, Doerffler, E., et al. (2012). Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 22, 2629-2634.
240. Shukla, R., Jowett, N.I., Thompson, D.R., and Pohl, J.E. (1994). Side effects with amiodarone therapy. Postgrad. Med. J. 70, 492-498.
241. Smith, D.A. (2010). Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of the Building Blocks of Medicinal Chemistry in ADMET. (Cambridge, UK: RSC Pub.).
242. Smith, D.A., Waterbeemd, H.d., and Walker, D.K. (2006). Pharmacokinetics and Metabolism in Drug Design, Second Edition. (Weinheim: Wiley-VCH).
243. Springer, J.P., Arison, B.H., Hirshfield, J.M., and Hoogsteen, K. (1981). The absolute stereochemistry and conformation of avermectin-B2a aglycon and avermectin-B1a. J. Am. Chem. Soc. 103, 4221-4224.
244. Stella, V.J., and He, Q. (2008). Cyclodextrins. Toxicol. Pathol. 36, 30-42.
245. Stephens, R.H., O'Neill, C.A., Bennett, J., Humphrey, M., Henry, B., Rowland, M., and Warhurst, G. (2002). Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br. J. Pharmacol. 135, 2038-2046.
246. Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G.F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010). Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9, 597-614.
247. Summa, V., Ludmerer, S.W., McCauley, J.A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P.J., Dimuzio, J.M., Ferrara, M., Di Filippo, M., et al. (2012). MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56, 4161-4167.
248. Surade, S., and Blundell, T.L. (2012). Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19, 42-50.
249. Tada, H., Tsuchiya, N., Satoh, S., Kagaya, H., Li, Z., Sato, K., Miura, M., Suzuki, T., Kato, T., and Habuchi, T. (2005). Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant. Proc. 37, 1730-1732.
250. Tan, E.Y., Hartmann, G., Chen, Q., Pereira, A., Bradley, S., Doss, G., Zhang, A.S., Ho, J.Z., Braun, M.P., Dean, D.C., et al. (2010). Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab. Dispos. 38, 459-473.
251. Taub, M.E., Mease, K., Sane, R.S., Watson, C.A., Chen, L., Ellens, H., Hirakawa, B., Reyner, E.L., Jani, M., and Lee, C.A. (2011). Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug Metab. Dispos. 39, 2093-2102.
252. Terhaag, B., Donath, F., Le Petit, G., and Feller, K. (1986). The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. Int. J. Clin. Pharmacol. Ther. Toxicol. 24, 298-302.
253. Terrett, N.K. (2010). Methods for the synthesis of macrocycle libraries for drug discovery. Drug Discov. Today. Technol. 7, e95-e146.
254. Terrett, N. (2013). Drugs in middle space. MedChemComm 4, 474-475.
255. Thomas, V.H., Bhattachar, S., Hitchingham, L., Zocharski, P., Naath, M., Surendran, N., Stoner, C.L., and El-Kattan, A. (2006). The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol. 2, 591-608.
256. Thompson, G.R., 3rd, and Wiederhold, N.P. (2010). Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170, 291-313.
257. Thomsonreuters (2013). Thomsonreuter: Integrity. http://thomsonreuters.com/integrity/. Last accessed Dec 2013.
258. Tian, X., Li, J., Zamek-Gliszczynski, M.J., Bridges, A.S., Zhang, P., Patel, N.J., Raub, T.J., Pollack, G.M., and Brouwer, K.L.R. (2007). Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother. 51, 3230-3234.
259. Togami, K., Chono, S., and Morimoto, K. (2012). Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Pharmazie 67, 389-393.
260. Tomilo, D.L., Smith, P.F., Ogundele, A.B., Difrancesco, R., Berenson, C.S., Eberhardt, E., Bednarczyk, E., and Morse, G.D. (2006). Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 26, 341-346.
261. Torres, H.A., Hachem, R.Y., Chemaly, R.F., Kontoyiannis, D.P., and Raad, I.I. (2005). Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5, 775-785.
262. Trellu, M., Filali-Ansary, A., Franc¸on, D., Adam, R., Lluel, P., Dubruc, C., and Thénot, J.P. (2004). New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. Fundam. Clin. Pharmacol. 18, 493-501.
263. Varma, M.V., Ambler, C.M., Ullah, M., Rotter, C.J., Sun, H., Litchfield, J., Fenner, K.S., and El-Kattan, A.F. (2010). Targeting intestinal transporters for optimizing oral drug absorption. Curr. Drug Metab. 11, 730-742.
264. Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., and Kopple, K.D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623.
265. Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., and Van Hecke, A. (2013). Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat. Rev. 39, 610-621.
266. Vieth, M., and Sutherland, J.J. (2006). Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49, 3451-3453.
267. Virshup, A.M., Contreras-García, J., Wipf, P., Yang, W., and Beratan, D.N. (2013). Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. J. Am. Chem. Soc. 135, 7296-7303.
268. von Hentig, N. (2008). Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 44, 103-132.
269. Vredenburg, M.R., Ojima, I., Veith, J., Pera, P., Kee, K., Cabral, F., Sharma, A., Kanter, P., Greco, W.R., and Bernacki, R.J. (2001). Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J. Natl. Cancer Inst. 93, 1234-1245.
270. Wachsman, M., Petty, B.G., Cundy, K.C., Jaffe, H.S., Fisher, P.E., Pastelak, A., and Lietman, P.S. (1996). Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res. 29, 153-161.
271. Wager, T.T., Chandrasekaran, R.Y., Hou, X., Troutman, M.D., Verhoest, P.R., Villalobos, A., and Will, Y. (2010). Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci. 1, 420-434.
272. Wakenhut, F., Tran, T.D., Pickford, C., Shaw, S., Westby, M., Smith-Burchnell, C., Watson, L., Paradowski, M., Milbank, J., Stonehouse, D., et al. (2014). The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2. ChemMedChem 9, 1387-1396, http://dx.doi.org/10.1002/cmdc.201400046.
273. Walters, W.P. (2012). Going further than Lipinski's rule in drug design. Expert Opin. Drug Discov. 7, 99-107.
274. Walz, D.T., DiMartino, M.J., and Griswold, D.E. (1983). The pharmacological profile of auranofin, an orally active gold compound. Scand. J. Rheumatol. Suppl. 51, 16-25.
275. Waring, M.J. (2009). Defining optimum lipophilicity and molecular weight ranges for drug candidates - molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett. 19, 2844-2851.
276. Watashi, K. (2010). Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr. Opin. Investig. Drugs 11, 213-224.
277. White, T.R., Renzelman, C.M., Rand, A.C., Rezai, T., McEwen, C.M., Gelev, V.M., Turner, R.A., Linington, R.G., Leung, S.S., Kalgutkar, A.S., et al. (2011). On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol. 7, 810-817.
278. Wildfeuer, A., Laufen, H., and Zimmermann, T. (1996). Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob. Agents Chemother. 40, 75-79.
279. Williamson, B., Dooley, K.E., Zhang, Y., Back, D.J., and Owen, A. (2013). Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob. Agents Chemother. 57, 6366-6369.
280. Wils, P., Warnery, A., Phung-Ba, V., Legrain, S., and Scherman, D. (1994). High lipophilicity decreases drug transport across intestinal epithelial cells. J. Pharmacol. Exp. Ther. 269, 654-658.
281. Wu, C., Decker, E.R., Blok, N., Li, J., Bourgoyne, A.R., Bui, H., Keller, K.M., Knowles, V., Li, W., Stavros, F.D., et al. (2001). Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist. J. Med. Chem. 44, 1211-1216.
282. Xu, J., Go, M.L., and Lim, L.Y. (2003). Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit, and pummelo. Pharm. Res. 20, 169-176.
283. Xu, L., Liu, H., Murray, B.P., Callebaut, C., Lee, M.S., Hong, A., Strickley, R.G., Tsai, L.K., Stray, K.M., Wang, Y., et al. (2010). Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med. Chem. Lett. 1, 209-213.
284. Yang, Y., Engkvist, O., Llinàs, A., and Chen, H. (2012). Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds. J. Med. Chem. 55, 3667-3677.
285. Yang, H., Robinson, M., Corsa, A.C., Peng, B., Cheng, G., Tian, Y., Wang, Y., Pakdaman, R., Shen, M., Qi, X., et al. (2014). Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob. Agents Chemother. 58, 647-653.
286. Yu, X., and Sun, D. (2013). Macrocyclic drugs and synthetic methodologies toward macrocycles. Molecules 18, 6230-6268.
287. Zhanel, G.G., Dueck, M., Hoban, D.J., Vercaigne, L.M., Embil, J.M., Gin, A.S., and Karlowsky, J.A. (2001). Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61, 443-498.
288. Zhang, M.-Q., and Wilkinson, B. (2007). Drug discovery beyond the 'rule-of-five'. Curr. Opin. Biotechnol. 18, 478-488.
289. Zhang, Y., Bachmeier, C., and Miller, D.W. (2003). In vitro and in vivo models for assessing drug efflux transporter activity. Adv. Drug Deliv. Rev. 55, 31-51.
290. Zhang, D., Chando, T.J., Everett, D.W., Patten, C.J., Dehal, S.S., and Humphreys, W.G. (2005a). In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739.
291. Zhang, Y., Gupta, A., Wang, H., Zhou, L., Vethanayagam, R.R., Unadkat, J.D., and Mao, Q. (2005b). BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22, 2023-2034.